[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635263":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":29,"locations":36,"responsibleParty":49,"collaborators":25,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":25,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":25,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":73,"overallStatus":75,"whyStopped":25,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Pak Emirates Military Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group A","EXPERIMENTAL","Group A will receive 1 g of intravenous calcium chloride diluted in 100 mL of normal saline, administered over 10 minutes beginning one minute after cord clamping, in addition to standard oxytocin therapy (10 IU intravenous bolus followed by 20 IU infusion).",[13],"Drug: Calcium Chloride",{"label":15,"type":16,"description":17,"interventionNames":18},"Group B","PLACEBO_COMPARATOR","Group B will receive standard care with oxytocin alone.",[19],"Other: Placebo",[21,26],{"type":22,"name":23,"description":11,"armGroupLabels":24,"otherNames":25},"DRUG","Calcium Chloride",[9],null,{"type":6,"name":27,"description":17,"armGroupLabels":28,"otherNames":25},"Placebo",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":34,"email":35},"Sumera Maqbool, MBBS","CONTACT","+92 344 5346622","+92","Sumeramaqbool777@gmail.com",[37],{"facility":5,"status":25,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":25},"Rawalpindi","Punjab Province","44000","Pakistan","PK",{"type":44,"coordinates":45},"Point",[46,47],73.0479,33.59733,{"lat":47,"lon":46},{"type":50,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Salma Nisar","Senior Registrar","100635263","phase-2-role-of-intravenous-calcium-to-decrease-blood-loss-during-intrapartum-cesarean-section-100635263",false,"NCT07550413","Role of Intravenous Calcium to Decrease Blood Loss During Intrapartum Cesarean Section","Inclusion Criteria:\n\n* Women aged 18-45 years undergoing intrapartum cesarean section at ≥34 weeks of gestation.\n* Exposure to oxytocin during labor before CS.\n* Singleton pregnancy with no known fetal anomalies.\n\nExclusion Criteria:\n\n* Known bleeding disorders or preoperative coagulation abnormalities\n* Preeclampsia or hypertensive disorders contraindicate calcium use.\n* History of cardiac disease or arrhythmias\n* Placental abnormalities, i.e., placenta previa, accreta\n* Emergency CS with fetal distress or cord prolapse.\n* Known hypersensitivity to calcium chloride.",true,"FEMALE","18 Years","45 Years",{"count":64,"type":65},182,"ESTIMATED","INTERVENTIONAL",[68],"PHASE2","To determine the effectiveness of prophylactic intravenous calcium chloride administered after cord clamping in reducing postpartum blood loss during intrapartum cesarean section.",[71,72],"Post Partum Haemorrhage","Cesarean Section Surgery",[74],"Randomized Controlled Trial","NOT_YET_RECRUITING","2026-04-19",{"date":78,"type":79},"2026-04-24","ACTUAL",{"date":81,"type":65},"2026-05",{"date":83,"type":65},"2026-12",{"name":5,"class":6},1]